Entera Bio Ltd. (ENTX) News
Track canonical SquawkNews coverage tagged to ENTX, Entera Bio Ltd.. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 10 indexed stories across 6 publication days and is ordered by the same first-publication timeline used by LiveCast.
M
Entera Bio Presents Phase 2 Data on EB613
Entera Bio presents Phase 2 data on osteoporosis treatment
EQUITY | Aug 04, 2026, 12:31 PM UTC
L
ENTX to Participate in Canaccord Conference
ENTX to present at conference
EQUITY | Jul 31, 2026, 08:30 PM UTC
L
ENTX ENTX - Greenberg Traurig Advises Entera Bio in Record $275M Israeli Biotech PIPE
ENTX ENTX - Greenberg Traurig Advises Entera Bio in Record $275M Israeli Biotech PIPE
EQUITY | Jul 29, 2026, 07:00 PM UTC
L
ENTX - Entera Bio Announces Pricing of Oversubscribed $275 Million Private Placement
ENTX - Entera Bio Announces Pricing of Oversubscribed $275 Million Private Placement
EQUITY | Jul 27, 2026, 12:31 PM UTC
H
NXTS Plunges 48%
NXTS leads small cap negative movers premarket, down 48% on momentum, followed by WHLR, KIDZ, and others
EQUITY | Jun 23, 2026, 12:22 PM UTC
M
Healthcare Stocks Move
Gainers Catheter Precision (AMEX: VTAK ) shares rose 78.2% to $1.55 during Monday's after-market session. The company's market cap stands at $2.2 million. Allarity Therapeutics (NASDAQ: ALLR ) stock increased by 8.08% to
EQUITY | Jun 22, 2026, 09:10 PM UTC
M
ENTX Receives FDA Feedback
Entera Bio receives FDA's positive feedback for its Phase 3 registrational protocol for EB613 tablet to treat osteoporosis
EARNINGS | Jun 22, 2026, 05:23 PM UTC
M
Healthcare Stocks Moving
Multiple healthcare stocks are moving in Monday's intraday session, with gainers including Tenon Medical and Aditxt, and losers including Aethlon Medical and Atlantic International
EQUITY | Jun 22, 2026, 05:23 PM UTC
L
ENTX Vol Pops
ENTX volume is popping
EQUITY | Jun 22, 2026, 04:16 PM UTC
H
ENTX Receives FDA Feedback
ENTX - Entera Bio Receives Positive FDA Feedback on 12-Month Registrational Phase 3 Study for EB613 - the First Oral Anabolic Tablet in Development for Postmenopausal Women with Osteoporosis
EQUITY | Jun 22, 2026, 12:31 PM UTC